The Central Protocol and Data Monitoring Office (CPDMO) is a Shared Resource that provides a number of centralized clinical research protocol-related services. The primary objectives of the CPDMO Shared Resource are to support Cancer Center clinical investigators by providing assistance in developing high quality clinical protocols, ensuring that all appropriate institutional and Federal reviews have been accomplished prior to accruing participants, providing standard order sets for therapeutic protocols, ensuring appropriate research participant enrollment via a centralized clinical trial registration system, coordinating efforts to design and develop case report forms, ensuring appropriate scientific review, and monitoring of clinical research studies. The CPDMO is a key component of the Clinical Trials Infrastructure. It was proposed by the Clinical Academic Council and approved by the Director in 1995, replacing the Protocol Office which previously managed clinical research protocols. The CPDMO has grown from 5.5 FTEs to 26 FTEs (including the Investigational Studies Pharmacists) to meet the demands of an every-changing regulatory environment and to meet the institutional commitment to human subjects'protection and data integrity. A centralized research participant enrollment system was fully implemented in 1998, along with monitoring of protocol eligibility for 100% of participants who are enrolled on St. Jude protocols. In 1999, an automated clinical trials database application was installed. A program to monitor our institutional trials for protocol compliance, regulatory compliance and data quality was established in the fall of 2000. Therapeutic and non-therapeutic studies are monitored in accordance with the current Data and Safety Monitoring Plan (dated 2001). The office is heavily involved with the assurance of appropriate institutional, legal, scientific, and regulatory review of all clinical research protocols conducted at St. Jude. A recent review of processes showed that St. Jude's clinical research infrastructure is superior to that of benchmarked institutions, and provides researchers with unique opportunities that are unavailable elsewhere. The effort placed in monitoring and organization has had significant positive impact on the quality of research conducted at St. Jude. As the number of clinical trials with external collaborating sites increases, resources to support those sites have also been added, including monitors/auditors who review study information on site. Upgrades to the clinical trials database and enrollment system are ongoing to meet current and future needs. To meet the future needs of clinical research, the institutional clinical trials infrastructure will continue to evolve. The Institutional Data and Safety Monitoring Plan is being revised to incorporate a more risk-based approach to monitoring and auditing. The monitoring program will be moved into Cancer Center Operations in order to allow for real time monitoring of key aspects of the research. A separate institutional auditing function will review clinical research studies at regular intervals. Restructuring of CPDMO functions in the context of the Cancer Center and Institution will allow us to capitalize on strengths and to be good stewards of institutional resources.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA021765-34W1
Application #
8738011
Study Section
Special Emphasis Panel (ZCA1-RTRB-Z)
Project Start
2012-03-01
Project End
2014-02-28
Budget Start
2012-03-01
Budget End
2013-02-28
Support Year
34
Fiscal Year
2013
Total Cost
$802
Indirect Cost
$344
Name
St. Jude Children's Research Hospital
Department
Type
DUNS #
067717892
City
Memphis
State
TN
Country
United States
Zip Code
38105
Perez, Giselle K; Kirchhoff, Anne C; Recklitis, Christopher et al. (2018) Mental health insurance access and utilization among childhood cancer survivors: a report from the childhood cancer survivor study. J Cancer Surviv 12:528-536
Oladimeji, Peter O; Chen, Taosheng (2018) PXR: More Than Just a Master Xenobiotic Receptor. Mol Pharmacol 93:119-127
Wilson, Carmen L; Howell, Carrie R; Partin, Robyn E et al. (2018) Influence of fitness on health status among survivors of acute lymphoblastic leukemia. Pediatr Blood Cancer 65:e27286
Mueller, Emily L; Park, Elyse R; Kirchhoff, Anne C et al. (2018) Insurance, chronic health conditions, and utilization of primary and specialty outpatient services: a Childhood Cancer Survivor Study report. J Cancer Surviv 12:639-646
Wong, Timothy; Wang, Zhican; Chapron, Brian D et al. (2018) Polymorphic Human Sulfotransferase 2A1 Mediates the Formation of 25-Hydroxyvitamin D3-3-O-Sulfate, a Major Circulating Vitamin D Metabolite in Humans. Drug Metab Dispos 46:367-379
Triplett, Brandon M; Muller, Brad; Kang, Guolian et al. (2018) Selective T-cell depletion targeting CD45RA reduces viremia and enhances early T-cell recovery compared with CD3-targeted T-cell depletion. Transpl Infect Dis 20:
Crawford, Rebecca R; Potukuchi, Praveen K; Schuetz, Erin G et al. (2018) Beyond Competitive Inhibition: Regulation of ABC Transporters by Kinases and Protein-Protein Interactions as Potential Mechanisms of Drug-Drug Interactions. Drug Metab Dispos 46:567-580
Weil, Brent R; Madenci, Arin L; Liu, Qi et al. (2018) Late Infection-Related Mortality in Asplenic Survivors of Childhood Cancer: A Report From the Childhood Cancer Survivor Study. J Clin Oncol 36:1571-1578
Levine, Jennifer M; Whitton, John A; Ginsberg, Jill P et al. (2018) Nonsurgical premature menopause and reproductive implications in survivors of childhood cancer: A report from the Childhood Cancer Survivor Study. Cancer 124:1044-1052
Li, Jian-Feng; Dai, Yu-Ting; Lilljebjörn, Henrik et al. (2018) Transcriptional landscape of B cell precursor acute lymphoblastic leukemia based on an international study of 1,223 cases. Proc Natl Acad Sci U S A 115:E11711-E11720

Showing the most recent 10 out of 6764 publications